Home Healthcare Ovarian Cancer Market
ovarian cancer market

Ovarian Cancer Market, [By Tumor Type (Epithelial Ovarian Cancer, Ovarian Low Malignant Potential Tumor, Germ Cell Tumor, Sex Cord-Stromal Tumor), By Drug Class (Mitotic Inhibitors, Alkylating Agents, PARP Inhibitors, Antrheumatics, Antineoplastic, Others), By End Use (Hospital Pharmacies, Drug Stores, Online Pharmacies)]; and Geography - Trend, Analysis and Forecast till 2025

  • Published Date: Aug 2018
  • Pages: 0
  • Format: PDF
  • Report ID: PM1369
  • Base Year:
  • Historical Data:

Report Summary

Ovarian cancer is a type of cancer that affects the ovaries in female reproductive system. These ovaries are attached to the follicle, present on one each side of uterus. Ovaries produce ova and hormones like oestrogen and progesterone. Ovarian cancer cannot be easily detected, but is usually diagnosed as it spreads the pelvis and abdomen. In some cases, the early diagnosis helps in proper treating of the cancer by surgery or chemotherapy. Ovarian cancer is usually recognized by the symptoms such as abdominal bloating & swelling, weight loss, discomfort in the pelvis area, changes in the bowel habit, and frequent urination.

Diagnosis of ovarian cancer is majorly done by the procedures such as pelvic exam, imaging tests, blood test, and surgery. These test helps doctors in understanding the stage of the cancer. Generally, the stage starts from I to IV, where I stands for the lowest stage as it has affected only the ovaries. While, stage IV signifies the spread of cancer to distinct areas of the body. The treatment for this cancer majorly depends on the type and severity of the cancer. Basically, surgeries of the ovaries, and uterus are preferred for treating this cancer. Additional, chemotherapy drugs can be used in combination, and various options of targeted therapies can also be used. In recent past, there is a continuous growth observed in the number of patients suffering from ovarian cancer. For instance, a study presented by the American Cancer Association, there is an increase of patients suffering from ovarian cancer by 0.4% than last year.  The increasing number of women suffering from ovarian cancer has created a market potential during the forecast period.

Rising number of patients suffering from ovarian cancer, continuous need of effective treatment for treating ovarian cancer, and increasing awareness about this disease will support the growth of global ovarian cancer market.

The global ovarian cancer market is primarily driven by growing number of women suffering from ovarian cancer. As reported by the “American Cancer Society” in the U.S. for 2018 approximately 22,240 women are diagnosed with ovarian cancer. Moreover, ovarian cancer accounts for 5% of total women death in the U.S. out of all deaths. Additionally, increasing number of available treatment options for treating ovarian cancer, increasing incidences of smoking, and rising awareness for various other cancer treatments would also boost the entire market.

Increasing instances are observed for developing new drugs and targeted therapies via number of clinical trials. Also, the growing R&D funding and investments on healthcare by the developing and developed economies, and unmet needs for effective treatments influence the market growth during the forecast period. 

However, side effects caused due to chemotherapy, high cost of treatment and difficulty in diagnosis at early stage might hinder the growth of ovarian cancer in the near future.

Global Ovarian Cancer Market Taxonomy

The global ovarian cancer market is segmented on the basis of tumor type, drug class, end use and geography.

On the basis of tumor type, ovarian cancer market is segmented into:

  • Epithelial Ovarian Cancer
  • Ovarian Low Malignant Potential Tumour
  • Germ Cell Tumour
  • Sex Cord-Stromal Tumour

On the basis of drug class, ovarian cancer market is segmented into:

  • Mitotic Inhibitors
  • Alkylating Agents
  • PARP Inhibitors
  • Antirheumatics
  • Antineoplastic
  • Others

On the basis of end use type, ovarian cancer market is segmented into:

  • Hospital Pharmacies
  • Drug Store
  • Online Pharmacy

Geographically, the global ovarian cancer market is categorized into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. 

Large pool of patients suffering from ovarian cancer, rising focus on the cell research by various key players, and increasing healthcare expenditure to lead the growth of ovarian cancer market in North America region.

North America is expected to dominate the global ovarian cancer market over the forecast period. North America holds major share owing to the continuous technological developments through increasing R&D investments by the major players and government. While, increasing awareness for the use of biological therapies, gene therapy, combined drugs would also spur this market in North America.

However, Asia Pacific market for ovarian cancer is observed to grow at a faster rate due to major factors including increasing number of patients suffering from ovarian cancer, changing lifestyle, rising preference for sedentary lifestyle, huge unmet needs for diagnosis of ovarian cancer and increased government expenditure for developing healthcare infrastructure during upcoming years.

Key players in the global ovarian cancer market are:

  • Boehringer Ingelhium Inc.
  • Amgen, Inc.
  • Novartis AG
  • Eli Lily and Company
  • Novogen, Inc.
  • Genentech Inc.
  • Hoffmann-La Roche
  • Teva Pharmaceuticals
  • GlaxoSmithKline plc.
  • Jansenn Pharmaceuticals, Inc.
  • Bristol Myers Squibb Company
Key Take-Away
Polaris Market Research
Global Ovarian Cancer Drugs Market Size, Share - Industry Report 2025